Sugi Predict

Sugi Predict / Compounds / SCHEMBL8970047

SCHEMBL8970047

SCHEMBL8970047

C=Cc1cnc(N)c(C(=O)c2cccc(N3CCCN(C(=O)OC(C)(C)C)CC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 2/20 0.51
▸ SKP1 P63208 2/20 0.51
▸ SKP2 Q13309 2/20 0.51
▸ PRKCQ Q04759 11/20 0.49
▸ MAP4K4 O95819 1/20 0.46
▸ PRKCA P17252 3/20 0.43
▸ PRKCD Q05655 3/20 0.43
▸ PTPN11 Q06124 1/20 0.43
▸ ATR Q13535 2/20 0.41
▸ PDE10A Q9Y233 1/20 0.41
▸ SMARCA2 P51531 1/20 0.40
▸ SMARCA4 P51532 1/20 0.40
▸ PBRM1 Q86U86 1/20 0.40
▸ TGM2 P21980 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13857199 0.91 CKS1B (0.51) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL1479331 0.89 CKS1B (0.53) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL1481538 0.88 CKS1B (0.52) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL8970023 0.87 CKS1B (0.60) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL8970210 0.86 PRKCQ (0.49) PRKCQPRKCAPRKCD
SCHEMBL8969924 0.85 CKS1B (0.51) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL8970017 0.85 PRKCQ (0.55) PRKCQPRKCAPRKCD
SCHEMBL8969675 0.84 PRKCQ (0.69) CKS1BSKP1SKP2PRKCQMAP4K4
SCHEMBL8970152 0.84 PRKCQ (0.69) PRKCQPRKCAPRKCD
SCHEMBL1481443 0.84 PRKCQ (0.48) PRKCQPRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 — — US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 — — US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 — — US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 — — US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CKS1B 137/4885SKP1 386/4885SKP2 219/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CKS1B 137/4885SKP1 386/4885SKP2 219/4885
US-20090124602-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CKS1B 137/4885SKP1 386/4885SKP2 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.